Position of the Transparency Council – Adtralza (tralokinumab)

At its meeting on 22 May 2023, the Transparency Council adopted Opinion No. 53/2023 on the evaluation of the drug Adtralza (tralokinumab) under the drug programme B.124 “Treatment of patients with severe forms of atopic dermatitis (ICD-10: L20)”.

Publication in Public Information Bulletin (BIP)